TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02737605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Esketamine
Description: Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Esketamine
Description: Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Esketamine
Description: Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Esketamine
Description: Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Esketamine
Description: Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Esketamine
Description: Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Esketamine
Description: Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Esketamine
Description: Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Esketamine
Description: Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Esketamine
Description: Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Esketamine
Description: Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Esketamine
Description: Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive 400 mg Moxifloxacin orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive 400 mg Moxifloxacin orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive 400 mg Moxifloxacin orally.
Study: NCT03984890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 drops 800IU/d for 3 months

Intervention type: DRUG
Group type: OTHER
Intervention: Traditional treatment of CGD and TB
Description: Anti-tuberculosis drugs, interferon-gamma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional treatment of CGD and TB
Description: Anti-tuberculosis drugs, interferon-gamma
Study: NCT04002050

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy with Mindfulness Course
Description: The Cognitive Behaviour Therapy with Mindfulness (CBTm) Course for Public Safety Personnel is a brief psychoeducational course consisting of 5 classes (90 minutes each) occurring on a weekly basis. The CBTm course addresses the fundamentals of CBT and provides participants with practical strategies for managing stress (such as relaxation strategies, cognitive restructuring, goal setting, behavioural activation, and exposure therapy).
Study: NCT03629223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib TF2
Description: Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib TF2
Description: Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib TF2
Description: Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib TF2
Description: Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib TF3
Description: Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib TF3
Description: Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib TF3
Description: Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib TF3
Description: Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.
Study: NCT01461759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doctaxel
Description: Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles
Study: NCT03002259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone administered as a single IV injection after induction of anaesthesia, but before initiation of CPB. Prepare as a 20 mg/mL dexamethasone solution, made up with 0.9% saline to 10 ml.
Study: NCT01623908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronate
Description: 4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.
Study: NCT02737605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive 400 mg Moxifloxacin orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive 400 mg Moxifloxacin orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive 400 mg Moxifloxacin orally.
Study: NCT00495677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-00232798
Description: Solution, 20 mg. once daily, 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-00232798
Description: Solution, 150 mg. once daily, 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-00232798
Description: Solution, 5 mg. once daily, 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-00232798
Description: Solution, 40 mg. once daily, 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-00232798
Description: Solution, 300 mg. once daily, 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-00232798
Description: Solution, 400 mg. once daily, 10 days
Study: NCT00176800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate (TM)
Description: Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation treatments will be administered twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: The persons's esophagus will be surgically removed (esophagectomy) on approximately Day #50.
Study: NCT04251169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as 30 minutes IV infusion every 3 weeks beginning in Cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at the 80 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15 of every 21-day cycle (beginning in Cycle 2). On days of scheduled infusions of pembrolizumab and paclitaxel (i.e., Day 1 of every cycle), paclitaxel is to be administered after infusion of pembrolizumab
Study: NCT02745249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Nutrition Behavior change
Study: NCT01917942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Humidification
Description: Fisher and Paykel Healthcare MR880 humidifier + HC211 flow source. 37/44 Humidification (37oC at 100% relative humidity, 44 mg of water per litre of air, 25 litres per min initial flow rate). The patients will be instructed to use humidification from day 1 of the radiotherapy course as much as is practical; the preference is for continuous overnight humidification plus maximal use throughout the day.Humidification will continue throughout treatment until at least week 8 after the commencement of radiotherapy and will cease when the CTCAE mucositis (clinical exam) score becomes less than grade 2, or at the week 16 assessment, whichever is earliest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: SOC: institutional standard of care for the management of mucositis. SOC will be defined by each participating institution and be kept consistent at that institution for the duration of the study. In general, SOC will consist of rinsing with 50:50 salt bicarbonate of soda mouthwash; benzydamine mouthwash; appropriate analgesic, antimicrobial and antifungal protocols etc.
Study: NCT01240707

Intervention type: OTHER
Group type: OTHER
Intervention: Fiberoptic bronchoscopy
Description: Fiberoptic bronchoscopy performed to remove secretions and assess soot in central airways
Study: NCT04394897

Intervention type: COMBINATION_PRODUCT
Intervention: Remifentanil-Propofol admixture

Intervention type: COMBINATION_PRODUCT
Intervention: Remifentanil-Propofol admixture
Study: NCT05270941

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: COMPARISON OF PLATELET-RICH FIBRIN PREPARED WITH TITANIUM AND SUBEPITHELIAL CONNECTIVE TISSUE GRAFT
Description: In the study, 118 maxillary bilateral multiple Miller Class I gingival recessions in 20 patients were treated. The gingival recessions were randomly treated with either T-PRF (58 teeth) or SCTG (60 teeth) using the modified coronally positioned flap technique. Gingival index, plaque index, probing pocket depth, gingival thickness, recession height, recession width, keratinized gingival width, and open root surface area were measured and recorded at baseline and at the 6th month. Postoperative pain levels were evaluated using the VAS (Visual Analogue Scale), and healing status was evaluated using the wound healing index. The pre- and post-treatment results of both treatment groups and the differences between the groups were evaluated and compared.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: COMPARISON OF PLATELET-RICH FIBRIN PREPARED WITH TITANIUM AND SUBEPITHELIAL CONNECTIVE TISSUE GRAFT
Description: In the study, 118 maxillary bilateral multiple Miller Class I gingival recessions in 20 patients were treated. The gingival recessions were randomly treated with either T-PRF (58 teeth) or SCTG (60 teeth) using the modified coronally positioned flap technique. Gingival index, plaque index, probing pocket depth, gingival thickness, recession height, recession width, keratinized gingival width, and open root surface area were measured and recorded at baseline and at the 6th month. Postoperative pain levels were evaluated using the VAS (Visual Analogue Scale), and healing status was evaluated using the wound healing index. The pre- and post-treatment results of both treatment groups and the differences between the groups were evaluated and compared.
Study: NCT02606123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-506
Description: Patients will receive EPI-506 as an oral softgel capsule.~Part 1:~Approximately six dose levels of EPI-506 will be studied, beginning at 80 mg/day. During the Single-Dose Period, patients will first receive a dose of EPI-506 in the fasted state followed by 2 days of washout, and then patients will receive a second dose of EPI-506 in the fed state followed by 2 days of washout. Patients will then enter the Multiple Dosing and Long-term Dosing Period where they will receive once or twice daily dosing in a fed or fasted state until they meet discontinuation criteria.~Part 2:~The dose in Part 2 will be determined in Part 1 of the study. Patients will receive the Part 2 dose daily until they meet discontinuation criteria.
Study: NCT05221567

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Intensive psychotherapy (i.e., greater number of treatment sessions per time unit)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Intensive psychotherapy (i.e., greater number of treatment sessions per time unit)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychotherapy
Description: Intensive psychotherapy (i.e., greater number of treatment sessions per time unit)
Study: NCT02737605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Participants will receive matching placebo orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Participants will receive matching placebo orally.
Study: NCT01203306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab + octreotide LAR + capecitabine
Description: long acting octreotide acetate at a dose of 20 or 30 mg administered intramuscularly every 4 weeks; Bevacizumab at a dose of 5 mg/kg every 2 weeks; orally capecitabine administered at a dose of 2000 mg/daily
Study: NCT02737605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Participants will receive matching placebo orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Participants will receive matching placebo orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Participants will receive matching placebo orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Participants will receive matching placebo orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Participants will receive placebo 40 minutes, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Participants will receive placebo 40 minutes, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Participants will receive placebo 40 minutes, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Participants will receive placebo 40 minutes, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Participants will receive placebo 40 minutes, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Participants will receive placebo 40 minutes, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Placebo
Description: Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Placebo
Description: Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Placebo
Description: Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Placebo
Description: Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Placebo
Description: Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Placebo
Description: Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).
Study: NCT03566498

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immediate hydration
Description: They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Early hydration
Description: They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
Study: NCT02969759

Intervention type: OTHER
Group type: OTHER
Intervention: Skin Biopsy
Study: NCT01145404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Description: Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
Study: NCT02433782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial therapy
Description: Maneuver of pressure and sliding over the anterolateral compartment of the leg Maneuver of pressure and sliding on the back of the leg Liberation technique of the popliteal fascia Maneuver of pressure and sliding on the anterior thigh Maneuver of pressure and sliding on the iliotibial tract Maneuver of pressure and sliding on the hamstring muscle region. Induction maneuver of ankle anterior compartment Induction maneuver of knee anterior chamber
Study: NCT03971019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statins
Description: On the basis of dietary intervention. Simvastatin 20mg/d QN Po (half an hour before bedtime) (dosage can be adjusted according to other indicators of blood lipid level in each review), atorvastatin 10mg/d QN Po (half an hour before bedtime) (patients who can not tolerate the side effects of simvastatin can consider replacing this drug).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary intervention group (control group)
Description: Restriction of dietary components that increase LDL-C Saturated Fatty Acids Less than 7% of total energy Dietary cholesterol \< 300 mg/d Increasing Dietary Ingredients for Reducing LDL-C Phytosterol 2\~3 g/d Water soluble dietary fiber 10\~25 g/d total energy Adjusted to maintain ideal weight or lose weight Physical activity Maintain moderate intensity exercise and consume at least 200 kcal of calories per day
Study: NCT01608568

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device is the type of suture used: Quill suture vs. Interrupted suture
Description: To compare two methods of polypropylene mesh attachment during robotic assisted laparoscopic sacrocolpopexy (RALSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device is the type of suture used: Quill suture vs. Interrupted suture
Description: To compare two methods of polypropylene mesh attachment during robotic assisted laparoscopic sacrocolpopexy (RALSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
Study: NCT01437059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-PCS02
Description: Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion
Study: NCT01637402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Standard dose participants:~1,000 mg, once daily, oral administration.~Dose escalation participants:~1,000 mg, twice daily, oral administration
Study: NCT01437059

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study: NCT01637402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Standard dose participants:~1,000 mg, once daily, oral administration.~Dose escalation participants:~1,000 mg, twice daily, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg, twice daily, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg, twice daily, oral administration
Study: NCT00475072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000/1200mg po daily for 48 weeks
Study: NCT04324476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab、Oxaliplatin、Irinotecan、Capecitabine
Description: Drug: Bevacizumab 5mg/kg, iv, 30min, d1, 2w; Drug: Oxaliplatin 85mg/㎡, iv, 120min, d1, 4W; Drug: Irinotecan 150mg/㎡, iv, 90min, d15, 4w; Drug: Capecitabine 1000mg/㎡, bid, d2-8, 2w.
Study: NCT00102336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 531
Description: Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
Study: NCT03774836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: IV Tramadol 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine 4 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44